An Act to amend the Code of Virginia by adding a section numbered 32.1-45.5, relating to Department of Health; opioid antagonist distribution program; reports.
HB1063 adds a new section to the Code of Virginia requiring the Department of Health to maintain a list of agencies and organizations that request and receive opioid antagonists through the state’s distribution program. The Department must provide quarterly reports to specified legislative committees and the chair of the Virginia Opioid Abatement Authority identifying each recipient organization, its service area, and details about the most recent request and fulfillment, including quantities, formulations, dosages, and dates.
The bill also requires the Department to develop a methodology for estimating the program’s annual costs. That methodology must rely on available data and consider account saturation goals, community needs, local resources, and product costs. Using that methodology, the Department must submit an annual cost estimate for the following fiscal year to the Joint Commission on Health Care and the chairs of the House Appropriations and Senate Finance and Appropriations Committees by December 1 each year.
The bill does not change who may receive opioid antagonists, but it adds new reporting and planning duties for the Department of Health. It creates a recurring disclosure framework for legislative oversight of the opioid antagonist distribution program and requires annual cost forecasting, which may affect budgeting, appropriations planning, and program administration. The affected parties are the Department of Health, recipient agencies and organizations, legislative committees, and the Virginia Opioid Abatement Authority.
The available record shows no committee transcript or recorded vote debate, so there is no documented opposition or support to characterize from discussion. The bill’s enactment as chapter text suggests it moved successfully through the legislative process and was ultimately approved. Based on its content, the measure appears to have been treated as an oversight and administrative reporting bill rather than a controversial policy change.
No specific points of contention are reflected in the provided materials. Potential areas of interest, if debated, would likely have been the administrative burden of quarterly reporting, the privacy or operational implications of listing recipient organizations and service areas, and the reliability of the cost-estimation methodology. However, the record provided does not identify any member, agency, or stakeholder taking a formal opposing position.